Clay Siegall, Ph.D., the CEO of Immunome, has a wealth of experience in biotechnology. He carries a Ph.D. in Genetics from George Washington University and co-founded Seagen, Inc., where he was the CEO for nearly two decades. His leadership there...
Clay Siegall, Ph.D., the CEO of Immunome, has a wealth of experience in biotechnology. He carries a Ph.D. in Genetics from George Washington University and co-founded Seagen, Inc., where he was the CEO for nearly two decades. His leadership there helped shape the company until its recent acquisition by Pfizer. Dr. Siegall joined Immunome in 2023 following the merger with Morphimmune, where he served as CEO. His role now includes driving the company’s vision and ensuring it meets performance goals. In 2023, he received a salary of $162,500, along with a performance bonus of $483,600, showing his interests align with the company’s success. Additionally, he was granted stock options to buy over 2 million shares, which is contingent on his continued employment. Dr. Siegall’s journey reflects a strong commitment to advancing cancer treatments through biotechnology and a focus on research and development, setting the stage for Immunome's strategic growth in the industry.